RT Journal Article
SR Electronic
T1 GWAS of retinal vessel tortuosity identifies 85 novel loci recovering variants associated with disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.25.20139725
DO 10.1101/2020.06.25.20139725
A1 Mattia Tomasoni
A1 Ninon Mounier
A1 Eleonora Porcu
A1 Tanguy Corre
A1 Hana Abouzeid
A1 Murielle Bochud
A1 Sven Bergmann
YR 2020
UL http://medrxiv.org/content/early/2020/06/26/2020.06.25.20139725.abstract
AB Fundus pictures of the eye allow for non-invasive inspection of the microvasculature system of the retina which is informative on cardiovascular health. Automated image processing enables the extraction of morphometric properties of this system as quantitative features that can be used for modelling disease risks.Here we report the results of the largest genome-wide association study (GWAS) of retinal vessel tortuosity conducted to date using data from the UK Biobank (N=63,899). We identified 87 loci associated with this trait (85 of which are novel). The heritability of the trait was h2=0.23 (0.02). We carried out a replication study on a small independent population-based cohort, SKIPOGH (N=436). While the power of this study was too small to replicate individual hits, the effect size estimates correlated significantly between the two studies (Pearson correlation r=0.55, p=4.6E-6). Using LD score regression, we showed that the alleles associated with retinal vessel tortuosity point to a common genetic architecture of this trait with CVD and related traits.Our results shed new light on the genetics of cardiovascular risk factors and disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Swiss National Science Foundation (#FN 310030_152724/1). The SKIPOGH study was supported by the Swiss National Science Foundation (#FN 33CM30-124087).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:approval was obtained from the UK Biobank ethics commission.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are made available by the UK Biobank Consortium.